Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy (Q41184484)

28 September 2017

1 reference

title

Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy (English)

1 reference

28 September 2017

1 reference

1 reference

Bennett WM

1

1 reference

28 September 2017

DeMattos A

2

1 reference

28 September 2017

Meyer MM

3

1 reference

28 September 2017

Andoh T

4

1 reference

28 September 2017

Barry JM

5

1 reference

28 September 2017

language of work or name

English

0 references

publication date

1 October 1996

1 reference

28 September 2017

1 reference

28 September 2017

50

1 reference

28 September 2017

4

1 reference

28 September 2017

1089-1100

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.1996.415

28 September 2017

0 references

cites work

Causes of graft loss beyond two years in the cyclosporine era

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Progression of kidney disease in chronic renal transplant rejection

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Acute cyclosporine nephrotoxicity--prototype for a renal membrane signalling disorder

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Daily renal hypoperfusion induced by cyclosporine in patients with renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Mechanisms of the endothelial toxicity of cyclosporin A. Role of nitric oxide, cGMP, and Ca2+

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporin in therapeutic doses increases renal allograft vascular resistance.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine-associated chronic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

The long-term course of cyclosporine-associated chronic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Time course of the decline in renal function in cyclosporine-treated heart transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine nephrotoxicity in cardiac allograft patients--a seven-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Following an initial decline, glomerular filtration rate stabilizes in heart transplant patients on chronic cyclosporine

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine nephrotoxicity in lung transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

The incidence of renal failure in one hundred consecutive heart-lung transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Associations between cyclosporine therapy and interstitial fibrosis in renal allograft biopsies

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplantation period

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine-associated renal arteriopathy resulting in loss of allograft function

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Long-term efficacy and safety of cyclosporine in renal-transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

HLA-identical renal transplants: impact of cyclosporine on intermediate-term survival and renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Evaluation of kidney function in renal transplant patients receiving long-term cyclosporine

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine-induced sympathetic activation and hypertension after heart transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine, sympathetic activity, and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Renal histopathologic alterations in patients treated with cyclosporine for uveitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Evolution of ciclosporin nephrotoxicity in patients treated for autoimmune uveitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine-induced renal morphologic and immunohistologic changes in patients with chronic uveitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Nephrotoxicity of cyclosporin A in patients with newly diagnosed type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Kidney biopsy findings in cyclosporine-treated patients with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Morphologic renal changes during cyclosporine treatment of psoriasis. Studies on pretreatment and posttreatment kidney biopsy specimens

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

A prospective study of renal structure and function in psoriasis patients treated with cyclosporin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine: nephrotoxic effects and guidelines for safe use in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Chronic nephrotoxicity complicating cyclosporine treatment of chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Long-term effects of cyclosporine on renal function in liver transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Renal insufficiency and hypertension as long-term complications in liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporin A in refractory idiopathic nephrotic syndrome: 5 years clinical experience

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Effect of cyclosporin A on glomerular filtration rate in children with minimal change nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Société de Néphrologie

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Focal segmental glomerular sclerosis. To treat or not to treat? 1. It is worthwhile to give the adult patient with nephrotic syndrome the benefit of an adequate therapeutic trial?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Focal segmental glomerulosclerosis: to treat or not to treat? 2. Focal and segmental glomerulosclerosis is not a disease, but an untreatable lesion of unknown pathophysiology. Its treatment must not be uselessly hazardous

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Ciclosporin in the treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporin A inhibits prostaglandin E2 formation by rat mesangial cells in culture

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Studies in chronic cyclosporine nephrotoxicity in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Atrial natriuretic peptide blunts the cellular effects of cyclosporine in smooth muscle

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Increased platelet-derived growth factor in the kidneys of cyclosporin-treated rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Arginine feeding modifies cyclosporine nephrotoxicity in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Increases in Levels of Collagen Types I and IV Messenger Ribonucleic Acid in Murine Kidneys after Treatment with Ciclosporin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Chronic cyclosporine-induced nephropathy in the rat. A medullary ray and inner stripe injury.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Effect of CsA on the expression of renin and angiotensin type 1 receptor genes in the rat kidney.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Renal injury from angiotensin II-mediated hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cellular expression of angiotensin type-1 receptor mRNA in the kidney

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

The effect of conversion from cyclosporin to azathioprine on renin-containing cells in renal allograft biopsies

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Regulation of transforming growth factor-beta 1 and its receptor by cyclosporine in human T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporine enhances the expression of TGF-beta in the juxtaglomerular cells of the rat kidney

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Diltiazem in renal allograft recipients receiving cyclosporine

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion

1 reference

https://api.crossref.org/works/10.1038%2FKI.1996.415

7 January 2021

Identifiers

DOI

10.1038/KI.1996.415

1 reference

28 September 2017

1 reference